We’ve discussed the therapeutic index of a drug and some of the preclinical safety studies that may be performed. Let’s now use that knowledge to examine some real-world data on three drug candidates being considered for the treatment of diabetes. Refer to the descriptions of each of the listed assays and decide which of these candidates you would advance for further testing on the way to the clinic. Make your selection here, and also share your reasoning on the discussion board.

When evaluating the data on each compound, consider the following:

Non-GLP toxicology studies were performed in the rat and dog with the following safety observations:

Rat:

At a dose 18-fold higher than the predicted efficacious dose in human, there were no safety observations.

At a dose 31-fold higher than the predicted efficacious dose in human, a moderate elevation of plasma glucose was observed.

Dog:

At a dose 20-fold higher than the predicted efficacious dose in human, there were no safety observations.

At a dose 59-fold higher than the predicted efficacious dose in human, a significant 21% prolongation of the cardiac QTc interval was observed (consistent with inhibition of the Ikr potassium channel in the ventricles, which is coded by the hERG gene); this indicates a potential ventricular arrhythmia risk that can lead to sudden death. Abnormal gait was observed in one animal.

Non-GLP toxicology studies were performed in the rat and dog with the following safety observations:

Rat:

At a dose 30-fold higher than the predicted efficacious dose in human, there were no safety observations

At a dose 96-fold higher than the predicted efficacious dose in human, moderate (4X) increase in ALT and AST (liver enzymes indicative of possible liver injury) and hepatocellular hypertrophy were observed

Dog:

At a dose 23-fold higher than the predicted efficacious dose in human, there were no safety observations

At a dose 80-fold higher than the predicted efficacious dose in human, emesis 1 hr after dosing was observed. There was also a moderate decrease in plasma sodium (can lead to symptoms ranging from nausea/vomiting, to muscle weakness/spasms/cramps, to seizures & coma)

Non-GLP toxicology studies were performed in the rat and dog with the following safety observations:

Rat:

At a dose 0.7-fold higher than the predicted efficacious dose in human, there were no safety observations.

At a dose 1.7-fold higher than the predicted efficacious dose in human, a mild (2X) increase in ALT and AST (liver enzymes indicative of possible liver injury) was observed, as was valvulopathy (cardiac mitral valve fibrosis/thickening).

Dog:

At a dose 15-fold higher than the predicted efficacious dose in human, there were no safety observations.

At a dose 50-fold higher than the predicted efficacious dose in human, a 30% increase in heart rate was observed.